CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

    Not Recruiting
  • participants needed
  • sponsor
    Kai Lin Xu; Jun Nian Zheng
Updated on 21 January 2021
Jiang Cao, M.D., Ph.D.
Primary Contact
Affiliated hospital of Xuzhou medical college (6.1 mi away) Contact


CD19 expression on B cell frequently lost after CD19-targeting CAR-T therapy. In present study, we construct a CD22-targeting chimeric antigen receptor to overcome this issue.


CD19 is an ideal target with great potential for treating B-cell-derived hematological malignancies. Although the complete remission rate is as high as 93% by using CD19-targeting CAR-T technology, approximately 60% patients will have recurrent disease. Among all the recurrent patients, two thirds is revealed to loss their CD19 expression on B cell surface. For overcoming this issue, we establish a new chimeric antigen receptor containing humanized single chain antibody sequence to target CD22 molecule on B cells.

Condition Recurrent or Refractory B Cell Malignancy
Treatment CD22 CAR-T
Clinical Study IdentifierNCT02794961
SponsorKai Lin Xu; Jun Nian Zheng
Last Modified on21 January 2021

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note